Celastrol from 'Thunder God Vine' Protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 mapk in a rotenone model of parkinson's disease

Neurochemical Research

Volumn 39, Issue 1, 2014, Pages 84-96

  Choi, Bong Suk ^a,d   Kim, Hyool ^b   Lee, Hyo Jeong ^c   Sapkota, Kumar ^a,e   Park, Se Eun ^a   Kim, Seung ^c   Kim, Sung Jun ^a  

^a Chosun University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Kwangju University   (South Korea)

^d Jangheung research institute for mushroom industry   (South Korea)

^e TRIBHUVAN UNIVERSITY   (Nepal)

Author keywords

Celastrol; Dopaminergic cell; Mitochondria; Oxidative stress; Parkinson disease; Rotenone

Indexed keywords

CASPASE 3; CASPASE 9; CELASTROL; CYTOCHROME C; DRUG VEHICLE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ROTENONE;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL LESION; NEUROPROTECTION; PARKINSON DISEASE; PRESERVATION; PRIORITY JOURNAL; TRIPTERYGIUM WILFORDII;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARKINSON DISEASE; ROTENONE; TRITERPENES;

EID: 84892670789     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1193-y     Document Type: Article

References (45)

1. Ahn DK (1998) Illustrated book of Korean medicinal herbs. Kyo-Hak Publishing, Seoul
2. Brinker AM, Ma J, Lipsky PE, Raskin I (2007) Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68:732-766 (Pubitemid 46330437)
3. Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394:439-442
4. Celastrol MoritaT (2010) a new therapeutic potential of traditional chinese medicine. Am J Hypertens 23:821
5. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K et al (2006) Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72:1311-1321 (Pubitemid 44572192)
6. Sassa H, Takaishi Y, Terada H (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem Biophys Res Commun 172:890-897 (Pubitemid 20384507)
7. Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303:9-20
8. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatr 25:1341-1357 (Pubitemid 33022713)
9. Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH et al (2009) Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest 39:819-827
10. Abbott A (2002) Neurologists strike gold in drug screen effort. Nature 417:109 (Pubitemid 34506768)
11. Heemskerk J, Tobin AJ, Bain LJ (2002) Teaching old drugs new tricks. Meeting of the neurodegeneration drug screening consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci 25:494-506 (Pubitemid 35246314)
12. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C et al (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7:17
13. Cleren C, Calingasan NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 94:995-1004 (Pubitemid 41170587)
14. Chow AM, Brown IR (2007) Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 12:237-244 (Pubitemid 351199386)
15. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B (2009) Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci. doi: 10.1186/1471-2202- 10-109
16. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16(2):183-194
17. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53:S26-S38 (Pubitemid 36368560)
18. Greenamyre JT, Sherer TB, Betarbet R, Panov AV (2001) Complex I and Parkinson's disease. IUBMB Life 52:135-141 (Pubitemid 33731566)
19. Schapira AH (2004) Disease modification in Parkinson's disease. Lancet Neurol 3:362-368 (Pubitemid 38648857)
20. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306
21. Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317-324 (Pubitemid 35246417)
22. Greenamyre JT, Betarbet R, Sherer TB (2003) The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord Suppl 2:S59-S64 (Pubitemid 36952523)
23. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T et al (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100:1469-1479 (Pubitemid 46376213)
24. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH et al (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23:10756-10764 (Pubitemid 37499681)
25. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34:279-290
26. Deng YN, Shi J, Liu J, Qu QM (2013) Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int pii:S0197-0186(13)00128-9. doi: 10.1016/j.neuint.2013. 04.005 [Epub ahead of print]
27. Newhouse K, Hsuan SL, Chang SH, Cai B, Wang Y, Xia Z (2004) Rotenone induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol Sci 79:137-146 (Pubitemid 38660257)
28. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795 (Pubitemid 44622683)
29. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M et al (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347-372 (Pubitemid 351252260)
30. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH et al (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22:404-420 (Pubitemid 44294281)
31. Kim SJ, Kim JS, Cho HS, Lee HJ, Kim SY, Kim S et al (2006) Carnosol a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells. NeuroReport 17:1729-1733 (Pubitemid 44621573)
32. Sapkota K, Kim S, Park SE, Kim SJ (2011) Detoxified extract of Rhus verniciflua stokes inhibits rotenone-induced apoptosis in human dopaminergic cells, SH-SY5Y. Cell Mol Neurobiol 31:213-223
33. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47:161-170
34. Schapira AH (1999) Science, medicine, and the future: Parkinson's disease. BMJ 318:311-314 (Pubitemid 29195142)
35. Perier C, Vila M (2012) Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2(2):a009332
36. Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134:109-118 (Pubitemid 40403643)
37. Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4:365-375 (Pubitemid 37280175)
38. Borner C (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39:615-647 (Pubitemid 35454076)
39. Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG, Dixit VM (1996) Molecular ordering of the cell death pathway-Bcl-2 and Bcl-x (L) function upstream of ced-3-like apoptotic proteases. J Biol Chem 271:4573-4576 (Pubitemid 26074928)
40. Mielke K, Herdegen T (2000) JNK and p38 stresskinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 61:45-60 (Pubitemid 30100402)
41. Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396-405
42. Chipuk JE, Green DR (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18:157-164
43. Choi WS, Eom DS, Han BS, Kim WK, Han BH, Choi EJ et al (2004) Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem 279:20451-20460 (Pubitemid 38623492)
44. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD (2004) Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 322:778-786 (Pubitemid 39164421)
45. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S et al (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279:56053-56060 (Pubitemid 40066613)